南方医科大学学报 ›› 2022, Vol. 42 ›› Issue (5): 625-632.doi: 10.12122/j.issn.1673-4254.2022.05.01

• •    下一篇

持续释放CA4P和阿霉素的可注射水凝胶/短纤维复合物用于小鼠乳腺癌异种移植瘤联合化疗

王 婷,杨 铃,谢雨涵,程思宇,熊 敏,罗晓明   

  1. 成都医学院公共卫生学院,四川 成都 610500
  • 出版日期:2022-05-20 发布日期:2022-06-02

An injectable hydrogel/staple fiber composite for sustained release of CA4P and doxorubicin for combined chemotherapy of xenografted breast tumor in mice

WANG Ting, YANG Ling, XIE Yuhan, CHENG Siyu, XIONG Min, LUO Xiaoming   

  1. School of Public Health, Chengdu Medical College, Chengdu 610500, China
  • Online:2022-05-20 Published:2022-06-02

摘要: 目的 制备释放CA4P和阿霉素(DOX)的可注射性凝胶/短纤维复合物,并研究其用于局部注射的抗肿瘤效果。方法 采用电纺和冷冻切割法制备负载阿霉素的PELA短纤维(FDOX),荧光显微镜观察药物在纤维表面的分布,荧光分光光度计测定包封率和载药量。室温下将纤维分散到载CA4P的PLGA-PEG-PLGA三嵌段聚合物(GCA4P)溶液中,以获得载药水凝胶/短纤维复合材料GCA4P/FDOX。采用试管倒置法测定复合材料的温敏性。紫外分光光度计和荧光分光光度计分别检测CA4P和DOX的释放。体外采用CCK-8试剂检测GCA4P/FDOX复合物对MCF-7和4T1细胞的毒性。建立小鼠4T1异种移植瘤模型,通过监测30 d内肿瘤的生长情况评价局部注射GCA4P/FDOX复合物的抗肿瘤效果。在治疗后第21天,对肿瘤切片进行HE染色、免疫组化(Ki67)和免疫荧光(TUNEL)检测。结果 FDOX的平均长度为4.0±1.3 μm,载药量为(2.69±0.35)%,包封率为(89.70±0.12)%;DOX在纤维表面分布均匀,当温度升高到37 ℃时,复合材料可以在体外快速固化形成凝胶。复合材料的释放行为显示,CA4P在5 d内可完全释放,87%的DOX在30天内释放。在与GCA4P/FDOX共同孵育72 h后,仅有30.6%的MCF-7和28.9%的4T1细胞存活。动物实验结果显示,治疗30 d后,GCA4P/FDOX治疗组小鼠的肿瘤体积约771.9±76.9 mm3,肿瘤坏死组织和凋亡细胞明显增多,增殖细胞减少。结论 该凝胶短纤维复合药物控释体系可为肿瘤局部联合化疗提供新的策略。

关键词: 静电纺丝;短纤维;阿霉素;CA4P;药物释放系统

Abstract: Objective To prepare an injectable hydrogel/staple fiber composite loaded with combretastain A-4 disodium phosphate (CA4P) and doxorubicin (DOX) and evaluate its antitumor efficacy via intratumoral injection. Methods DOX-loaded PELA staple fibers (FDOX) were prepared using electro-spinning and cryo-cutting, and the drug distribution on the surface of the fibers was observed using a fluorescence microscope, and the encapsulation efficiency and loading capacity of FDOX were determined with a fluorospectro photometer. The fibers were then dispersed in CA4P-loaded PLGA-PEG-PLGA tri-block polymer solution at room temperature to obtain the hydrogel/staple fiber composite (GCA4P/FDOX). The thermo-sensitivity of this composite was determined by a test tube inverting method. An ultraviolet spectrophotometer and a fluorospectrophotometer were used to detect the release profile of CA4P and DOX, respectively. We observed in vivo gel formation of the composite after subcutaneous injection in mice. The in vitro cytotoxicity of GCA4P/FDOX composite in MCF-7 and 4T1 cells was assessed using cell Counting Kit-8 (CCK-8) reagent. In a mouse model bearing breast tumor 4T1 cell xenograft, we evaluated the antitumor efficacy of the composite by monitoring tumor growth within 30 days after intratumoral injection of the composite. HE staining, immunohistochemistry for Ki67 and immunofluorescence (TUNEL) assay were used for pathological examination of the tumor tissues 21 days after the treatments. Results The average length of FDOX was 4.0±1.3 μm, and its drug loading capacity was (2.69±0.35)% with an encapsulation efficiency of (89.70±0.12)%. DOX was well distributed on the surface of the fibers. When the temperature increased to 37 ℃, the composite rapidly solidified to form a gel in vitro. Drug release behavior test showed that CA4P was completely released from the composite in 5 days and 87% of DOX was released in 30 days. After subcutaneous injection, the composite solidified rapidly without degradation at 24 h after injection. After incubation with GCA4P/FDOX for 72 h, only 30.6% of MCF- 7 cells and 28.9% of 4T1 cells were viable. In the tumor-bearing mice, the tumor volume was 771.9±76.9 mm3 in GCA4P/FDOX treatment group at 30 days. Pathological examination revealed obvious necrosis of the tumor tissues and tumor cell apoptosis induced by intratumoral injection of G4A4P/FDOX. Conclusion As an efficient dual drug delivery system, this hydrogel/staple fiber composite provides a new strategy for local combined chemotherapy of solid tumors.

Key words: electro-spinning; staple fibers; doxorubicin; CA4P; drug delivery system